NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.500
-0.040 (-2.60%)
At close: Aug 13, 2025, 4:00 PM
1.500
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:51 AM EDT
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,389,582
Market Cap
24.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NNVC News
- 15 days ago - Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides - Accesswire
- 22 days ago - NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value - Accesswire
- 24 days ago - Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides - Accesswire
- 4 weeks ago - WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides - Accesswire
- 2 months ago - With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan - Accesswire
- 2 months ago - NanoViricides Measles Drug Development Animal Study is Imminent - Accesswire
- 2 months ago - NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Accesswire
- 3 months ago - The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan - Accesswire